Regencor Announces their new CEO
May 18 2022 | Press Release
San Carlos, CA (May 17, 2022) - Regencor, Inc., a
leading pre-clinical company in cardiac regeneration, announced today
the appointment of Sean Edwards as President and CEO. Former CEO and
co-founder Tom Okarma will remain with the company
as Executive Chairman and continue his involvement with daily
Through 20 years of experience as an executive and lawyer, Mr. Edwards has helped businesses and clients navigate sophisticated strategic, legal, and regulatory issues. Working with both public and private companies, Mr. Edwards has expertise in growing business enterprises and successfully building shareholder value.
“We are delighted to welcome
Sean to Regencor” said Tom Okarma,
Executive Chairman, and co-founder.
“We are pleased that we have sufficiently matured as a company to attract a senior executive with Sean's proven track record. He has held multiple senior executive positions in biopharma and has experience managing finance, corporate development, operations, product development and large clinical trials. We are all excited to start working with Sean to accelerate Regencor's growth trajectory.”
“I'm excited to be joining
Regencor at such a dynamic time” said Sean Edwards, CEO.
“Having worked across several therapeutic areas during my career, I haven't seen many technologies that hold this much promise. Regencor's technology has the potential to be a tremendous leap forward in our ability to treat myocardial infarction and heart failure.”
Over the course of his career, Mr. Edwards has raised over $200M in institutional financings and has negotiated the acquisition and license of technologies and intellectual property. Experienced in guiding drugs and devices through the FDA, Mr. Edwards has also led the commercial launch of national and international brands in the physician dispensed and OTC drug channels. Prior to his career in life sciences, he spent eight years as an attorney specializing in complex commercial litigation for national and international law firms.
Regencor is a privately held spin-out of Stanford
University that has received multiple awards from the National
Institutes of Health and the California Institute for Regenerative
Medicine. Its lead product is a first-in-class,
proprietary biologic that stimulates cardiac regeneration after
myocardial infarction (heart attack). The recombinant
protein drives the proliferation of heart muscle and vascular cells
exclusively within the infarct zone, resulting in a
substantial reduction in scar volume and the sustained clinical
improvement of heart function in large animals with and
without comorbidities. The specific parameters of functional improvement
reduce the incidence of Major Adverse Cardiac
Events (MACE), which are the traditional outcome measures in randomized
clinical trials. The therapeutic is administered
by non-invasive subcutaneous delivery and will be the world's first
outpatient therapy to restore heart function after
Regencor's pipeline includes pre-clinical stage products under development for cardiomyopathy-associated heart failure discovered with their whole proteome screening platform.
Learn more about Regencor
President & CEO
Executive Chairman & Cofounder
Tom Okarma, MD, PhD